SCIENTIFIC BACKGROUND

GBA

SCIENTIFIC BACKGROUND

Gaucher disease is an autosomal recessive disorder of glycosphingolipid catabolism caused by reduced or absent activity of the lysosomal enzyme β-glucocerebrosidase (GBA). It is caused by pathogenic variants in the GBA gene. The enzyme defect leads to the progressive accumulation of glucocerebroside (glucosylceramide) or glucosylsphingosine predominantly in the lysosomes of macrophages. With increasing storage, the macrophages increase in size and become so-called Gaucher cells, which can be detected predominantly in the spleen, liver, and bone marrow and are characteristic of the clinical appearance.

 

In Gaucher disease, a distinction is made between the non-neuronopathic and neuronopathic forms of the disease. The non-neuronopathic form (classic type I) shows a chronic course with hepatosplenomegaly, hematological changes, and bone involvement without neurological symptoms. This type is the most common, accounting for 95% of cases, although disease onset and clinical expression are variable. The neuronopathic form can be acute or chronic. The acute neuronopathic form (classic type II) is characterized by severe neurologic complications that usually lead to death within the first two years of life. The chronic neuronopathic type (classic type III) differentiates from the acute form by a later onset of the disease and less progression, and is usually associated with marked hepatosplenomegaly and severe bone involvement.

 

Two treatment strategies are available for the management of Gaucher disease. Enzyme replacement therapy involves intravenous administration of the recombinant enzyme, which degrades glucocerebrosides stored in Gaucher cells. Alternatively, substrate reduction therapy is available, which reduces the rate of synthesis of glucocerebroside, thereby preventing its accumulation. Substrate reduction therapy with the active ingredient eliglustat is designed for the long-term treatment of adult patients with Gaucher disease type I. The efficacy of eliglustat depends on the CYP2D6 metabolizer status of the patient. Therefore, CYP2D6 metabolizer type should be determined prior to starting therapy (Cerdelga summary of product characteristics).

 

Direct measurement of β-glucocerebrosidase activity in leukocytes should be performed prior to molecular genetic testing of the GBA gene (ACMG Practice Guideline, 2011).

 

References

Scott 2015, Drugs 75:1669 / Nagral 2014, J Clin Exp Hepatol 4:37 / Cassinerio et al. 2013, Eur J Intern Med. 25:117 / Grabowski 2012, Hematology Am Soc Hematol Educ Program 13 / Karaca et al. 2012, J Pediatr Endocr Met 25:957 / ACMG Practice Guideline, Wang et al. 2011, Genetics IN Medicine 13:457 / Bodamer et Hung 2010, Wien Med Wochenschr 160:600

GENES

GBA

ASSOCIATED TESTS

How to order

LATEST ARTICLES

Every year on April 25th, DNA Day celebrates the discovery of DNA’s double helix and the advances we’ve made in understanding genetics. D...

Read more

Neurodevelopmental disorders (NDDs) have diverse genetic origins, making diagnosis challenging. A new study analyzing over 1,100 pediatric patients f...

Read more

Colorectal cancer (CRC) remains one of the most prevalent and deadly cancers worldwide, with a significant number of cases presenting at an advanced ...

Read more

Carrier screening is a genetic test designed to identify whether an individual carries a gene with changes (mutations) associated with inherited diso...

Read more

Trisomy 13, also known as Patau syndrome, is a genetic condition in which cells in the body have three copies of chromosome 13 instead of two. The co...

Read more

The human brain develops through a complex series of events, with genes carefully regulating the formation of neurons and glial cells. A recent study...

Read more

Rare diseases affect between 300 and 400 million people worldwide – more than cancer and AIDS combined [1, 2], but despite this, many people face a...

Read more

Rosalind Elsie Franklin was a brilliant and meticulous research scientist whose interdisciplinary work made fundamental contributions to various area...

Read more

February, designated as Cancer Awareness Month, marks a time to reflect on the remarkable progress made in cancer research and to inspire hope for th...

Read more

Introduction Cardiovascular disease (CVD) is a major health issue as it remains a leading cause of death worldwide [1]. CVD is responsible for mor...

Read more